Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder

Katzman Martin A.; Nierenberg Andrew A.; Wajsbrot Dalia B.; Meier Ellen; Prieto Rita; Pappadopulos Elizabeth; Mackell Joan; Boucher Matthieu

首页> 外文期刊>Journal of clinical psychopharmacology >Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder

【24h】

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder

机译：抑郁症患者50毫克和100毫克的抑郁症状的改善速度与具有重症抑郁症的安慰剂相比

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose/Background: This post hoc analysis examined the time point at which clinically significant improvement in major depressive disorder (MDD) symptoms occurs with desvenlafaxine versus placebo.

机译：目的/背景：该后HOC分析检测了临床上显着改善的时间点（MDD）症状与Desvenlafaxine与安慰剂发生的影响。

著录项

来源
《Journal of clinical psychopharmacology》 |2017年第5期|共7页
作者
Katzman Martin A.; Nierenberg Andrew A.; Wajsbrot Dalia B.; Meier Ellen; Prieto Rita; Pappadopulos Elizabeth; Mackell Joan; Boucher Matthieu;
展开▼
作者单位

START Clin Mood &

Anxiety Disorders 32 Pk Rd Toronto ON M4W 2N4 Canada;

Massachusetts Gen Hosp Boston MA 02114 USA;

Pfizer Inc New York NY USA;

Pfizer Inc New York NY USA;

Pfizer GEP SLU Madrid Spain;

Pfizer Inc New York NY USA;

Pfizer Inc New York NY USA;

Pfizer Canada Inc Kirkland PQ Canada;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
desvenlafaxine; early improvement; major depressive disorder; time to remission;

机译：Desvenlafaxine;早期改善;重大抑郁症;缓解时间;

相似文献

外文文献
中文文献
专利

1. Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder [J] . Katzman Martin A., Nierenberg Andrew A., Wajsbrot Dalia B., Journal of clinical psychopharmacology . 2017,第5期

机译：抑郁症患者50毫克和100毫克的抑郁症状的改善速度与具有重症抑郁症的安慰剂相比
2. Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder [J] . SoaresC.N., FayyadR.S., Guico-PabiaC.J. Journal of clinical psychopharmacology . 2014,第1期

机译：地塞拉法辛50 mg / d可早期缓解抑郁症状，可作为重度抑郁症患者治疗成功的指标
3. Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis [J] . Clayton Anita H., Hwang Eunhee, Kornstein Susan G., International clinical psychopharmacology . 2015,第6期

机译：50和100 mg去甲文拉法辛与安慰剂对重度抑郁症患者性功能的影响：一项荟萃分析
4. Data-Driven Longitudinal Modeling and Prediction of Symptom Dynamics in Major Depressive Disorder: Integrating Factor Graphs and Learning Methods [C] . Arjun P. Athreya, Subho S. Banerjee, Drew Neavin, IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology . 2017

机译：重大抑郁症症状动态的数据驱动纵向建模与预测：集成因子图和学习方法
5. The impact of efficacious treatments for major depressive disorder on remission rates of specific symptoms: A re-analysis of the Treatment of Depression Collaborative Research Program. [D] . Stewart, Jeremy Gordon. 2009

机译：有效治疗重度抑郁症对特定症状缓解率的影响：《抑郁症治疗合作研究计划》的重新分析。
6. Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder [O] . Martin A. Katzman, Andrew A. Nierenberg, Dalia B. Wajsbrot, -1

机译：与安慰剂相比重度抑郁症患者使用地文拉法辛50 mg和100 mg抑郁症状改善的速度
7. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder [O] . Michael R Liebowitz, null null, Karen A Tourian, 2013

机译：一项双盲，随机，安慰剂对照研究，评估desvenlafaxine 10和50 mg /天在患有重度抑郁症的成人门诊患者中的疗效和耐受性

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅